Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives

Giovanni Scambia, Nicoletta Colombo, Pier Franco Conte, Sandro Pignata, Francesco Raspagliesi

Risultato della ricerca: Contributo in rivistaArticolo in rivista

17 Citazioni (Scopus)

Abstract

The past five years have yielded substantial developments in the management of advanced ovarian cancer. Initial promise shown by anti-angiogenic agents has translated into positive phase III trials in the front-line and recurrent settings. Nevertheless, several questions remain unanswered, including the most appropriate timing for initiation of anti-angiogenic therapy and patient selection for the various treatment approaches. This review article summarises the key results (including final overall survival data), from five pivotal phase III trials of bevacizumab, highlights emerging data with new maintenance strategies and considers unanswered questions and ongoing research to address uncertainties in treatment duration, re-exposure to bevacizumab in bevacizumab-pretreated patients and the potential integration of anti-angiogenic therapy into neoadjuvant treatment regimens.
Lingua originaleEnglish
pagine (da-a)335-348
Numero di pagine14
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume97
DOI
Stato di pubblicazionePubblicato - 2016

Keywords

  • Angiogenesis Inhibitors
  • Anti-angiogenic
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Bevacizumab
  • Clinical Trials, Phase III as Topic
  • Female
  • Front-line
  • Geriatrics and Gerontology
  • Hematology
  • Humans
  • Oncology
  • Ovarian Neoplasms
  • Ovarian cancer
  • Phase III
  • Vascular endothelial growth factor

Fingerprint Entra nei temi di ricerca di 'Bevacizumab in ovarian cancer: Focus on clinical data and future perspectives'. Insieme formano una fingerprint unica.

Cita questo